House Joint Resolution 80, sponsored by Leatherwood, aims to designate May 2025 as "National Hypertension Month" to raise awareness about hypertension, a condition affecting nearly half of U.S. adults and a significant contributor to cardiovascular diseases. The resolution highlights the severe health complications associated with untreated hypertension, including heart disease and stroke, and emphasizes the need for improved management and treatment options. It notes that only about 25% of adults with hypertension have it under control and that healthcare costs related to hypertension are substantial, amounting to approximately $131 billion annually.

The resolution advocates for greater access to innovative therapies, particularly FDA-approved renal denervation treatments, which have shown promise for patients with resistant hypertension. It encourages healthcare providers, public health organizations, and community groups to engage in initiatives that promote hypertension awareness and management. Additionally, it calls for the inclusion of renal denervation therapies in health insurance coverage and urges the Department of Health to support best practices for hypertension management, including potential Medicaid coverage for innovative treatments.